Aelis Farma SA (EPA:AELIS)
France · Delayed Price · Currency is EUR 1.355
+0.215 (18.86%)
Sep 15, 2025, 4:29 PM CET
Aelis Farma Company Description
Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France.
The company is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug candidate, which is in phase II clinical trials to treat cognitive deficits observed in down syndrome, as well as other cognitive impairments.
Aelis Farma SA was incorporated in 2013 and is headquartered in Bordeaux, France.
Aelis Farma SA
| Country | France |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 28 |
| CEO | Pier Piazza |
Contact Details
Address: 1 rue Lafaurie de Monbadon Bordeaux, 33 000 France | |
| Phone | 33 5 54 54 23 27 |
| Website | aelisfarma.com |
Stock Details
| Ticker Symbol | AELIS |
| Exchange | Euronext Paris |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | FR0014007ZB4 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Pier Vincenzo Piazza M.D., Ph.D. | Chief Executive Officer and Director |
| Marie Line Lefevre | Head of Finance |
| Stephanie Monlezun | Chief Operating Officer |
| Lea Floquet | Head of Legal |
| Arsene Guekam | Chief Corporate Development Officer |
| Sandy Fabre | Head of Discovery and IP Leader |
| Aurelie Boucard | Head of Preclinical Development |
| Helle Mengel | Head of Clinical Development |
| Corinne Chaimbault | Head of Pharmaceutical Development |